# Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

> **NCT06092645** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Bile Duct Adenocarcinoma

## Interventions

- **DRUG:** surufatinib plus cadonilimab

## Key facts

- **NCT ID:** NCT06092645
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-30
- **Primary completion:** 2024-10-01
- **Final completion:** 2025-10-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06092645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06092645, "Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06092645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*